COMPANY RESEARCHStylus combines engineered recombinases with cell-targeted LNP delivery to create durable in vivo CAR-T through sequence-specific insertion. Its platform disclosure establishes preclinical research intent and mechanism, not patient benefit or demonstrated clinical safety.
Announcement date; not an additional US$85 million round.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Stylus combines engineered recombinases with cell-targeted LNP delivery to create durable in vivo CAR-T through sequence-specific insertion. Its platform disclosure establishes preclinical research intent and mechanism, not patient benefit or demonstrated clinical safety.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| Recombinase / targeted LNP CAR-T | See program source; distinguish indications | Preclinical | No human CAR-T evidence verified in this review. |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
A Nature study delivered guide RNA and base-editor mRNA in GalNAc lipid nanoparticles to inactivate liver ANGPTL3. Nonhuman primates showed mean ANGPTL3 protein reductions exceeding 90%, with durability assessed through three years after one dose. Lipid reductions were observed in animal models. Human liver-cell testing assessed selected off-target sites; the paper does not report human clinical efficacy.
A Nature Materials study describes mRNA-loaded LNPs that reprogram tumor-associated macrophages into Claudin18.2-targeting CAR macrophages. The lipid formulation also promotes TREM2 internalization and degradation, reshaping immune responses. The original abstract reports tumor suppression and longer survival with PD-1 blockade in mice, plus ex vivo patient-sample findings. These findings do not demonstrate clinical efficacy in treated patients.
CSPC announced initiation of the first Chinese center for SYS6055-003, a Phase 1/2 trial in relapsed or refractory B-cell non-Hodgkin lymphoma. SYS6055 uses lentiviral vectors to generate CD19-targeting CAR-T cells in vivo. The company said recruitment and screening are underway following October clinical-trial authorization. Center initiation does not establish patient dosing, efficacy, or marketing approval.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.